Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 111

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 111
---
 to the Purchaser in writing;                                     |

| (v) | entered into any collective bargaining agreement or Contract with any employee association, trade union, labour 
 organization or similar entity;                                                                                 |

| (vi) | waived or cancelled any right, claim or debt owed to it; |

| (vii) | transferred, assigned, sold or otherwise disposed of any of its assets exceeding $1,000,000 in value in the 
 aggregate;                                                                                                  |

| (viii) | incurred or assumed or guaranteed any liability, obligation or expenditure of any nature, absolute or                                     
 contingent, other than liabilities incurred in connection with the Discontinuance and in an amount less than $1,000,000 in the aggregate; |

| (ix) | committed to make or perform any capital expenditures or maintenance or repair projects, except for capital                                              
 expenditures or maintenance or repair projects incurred in connection with the Discontinuance with a value not greater than $1,000,000 in the aggregate; |

| (x) | entered into any commitment or transaction not in connection with the Discontinuance; |

| (xi) | entered into or authorized or agreed to any material changes in any Material Contract; |

| (xii) | entered into any Contract with a Related Party; |

| (xiii) | made or agreed to make any bonus or profit-sharing distribution or similar payment of any kind, other than 
 bonuses to employees in connection with the Discontinuance;                                                |

| (xiv) | arranged any debt financing or incurred or materially increased its indebtedness for borrowed money; |

| (xv) | made any change in any method of accounting or auditing practice except as disclosed in the Financial 
 Statements;                                                                                           |

| (xvi) | hypothecated, pledged, subjected to an Encumbrance, granted a security interest in or otherwise encumbered any 
 of its material assets whether tangible or intangible other than in connection with the Discontinuance;        |

| (xvii) | made any material gift of money or of any property or assets to any individual or person; or |

| (xviii) | authorized, agreed or otherwise become committed to do any of the foregoing. |

E-5

| 15. | Derivative Transactions |

Neither the Company nor its Subsidiary has any material obligations or liabilities, direct or indirect, vested or contingent in respect of any streaming transactions, rate swap transactions, basis swaps, forward rate